Open access peer-reviewed chapter - ONLINE FIRST

Microvascular Complications of Diabetes Mellitus: Focus on Diabetic Retinopathy (DR) and Diabetic Foot Ulcer (DFU)

By Ana Maria Dascalu, Dragos Serban, Nikolaos Papanas, Peter Kempler, Manfredi Rizzo, Daniela Stana, Gabriela Roman and Anca Pantea-Stoian

Submitted: September 22nd 2020Reviewed: February 9th 2021Published: March 10th 2021

DOI: 10.5772/intechopen.96548

Downloaded: 49

Abstract

Diabetic retinopathy and diabetic foot ulcer are the most frequent, but also the most disabling complications of diabetes mellitus, with a sinister impact on patients’ quality of life. Microvascular changes related to the deleterious effect of chronic hyperglycemia play an important role in the pathophysiology of both clinical entities by multiple molecular pathways. Vision-threating diabetic retinopathy may be treated by laser photocoagulation, anti-vascular endothelial growth factor (VEGF) agents and vitreoretinal surgery. Diabetic foot lesions are best treated by revascularization if needed, off-loading, infection control and therapeutic adjuncts (e.g. special dressings). Treatment should ideally be offered by a multidisciplinary expert team. Prevention and early detection, along with adequate control of glucose, lipids and arterial hypertension are of paramount importance to avoid and mitigate these fearful complications.

Keywords

  • microvascular complications
  • diabetic retinopathy
  • risk factors
  • ophthalmoscopy
  • angiography
  • laser photocoagulation
  • diabetic foot
  • diabetic neuropathy
  • treatment

1. Introduction

In diabetes (DM), chronic complications related to the direct or indirect effects of prolonged hyperglycemia on the vasculature have been classified into macrovascular and microvascular complications, depending on the size of affected vessels and the pathophysiological mechanisms involved. Microvascular disease includes retinopathy, nephropathy and neuropathy.

Diabetic retinopathy, one of the first manifestations of microvascular disease, remains today, despite improvements in monitoring and treatment, one of the leading causes of blindness worldwide. Epidemiological studies estimate that approximately 40% of subjects with DM type I over 40 years of age have retinal microvascular changes, of which 8.2% exhibit impaired visual acuity [1, 2]. Both DM types are associated with impaired retinal microcirculation. After 20 years from the onset of DM, almost all patients with type 1 DM (T1DM) and over 60% of those with type 2 DM (T2DM) will be affected [3]. Furthermore, decreased vision as a result of diabetic retinopathy has a negative impact on the quality of life of patients and their ability to successfully manage DM [4].

Diabetic foot results from diabetic neuropathy and/or peripheral arterial disease and affects annually between 9.1 to 26.1 million [5]. It is a chronic disabling and progressive complication, with potential deformities, chronic ulcerations and infections. Diabetic foot ulcers (DFUs) are encountered in 15% of DM patients, of whom 15-20% reach amputations. The latter lead to increased morbidity and decreased quality of life, but also an important burden on national healthcare systems, with increased health costs and hospitalization [6, 7].

Advertisement

2. Diabetic retinopathy

2.1 Risk factors

2.1.1 DM duration and poor glycemic control

Diabetic retinopathy (DR) is a chronic complication associated with long DM duration and poor glycemic control, the overall incidence of DR and of vision-threatening forms of DR (VTDR) being higher in T1DM than in T2DM [8]. The United Kingdom Prospective Diabetes Study (UKPDS) showed that both the incidence and progression of DR correlate with elevated HbA1c, emphasizing the importance of good glycemic control to prevent visual impairment [9]. Every 1% decrease in HbA1c leads to a 40% reduction in the risk of developing retinopathy, a 25% reduction in the risk of progression to vision-threatening retinopathy, and a 15% reduction in the risk of blindness [10].

2.1.2 Arterial hypertension

The correlations between cardiovascular risk factors and the occurrence and evolution of DR are still a subject of study. However, there is clear evidence that the processes of arteriolosclerosis and the mechanical trauma to the vascular endothelium caused by elevated systolic and diastolic blood pressure are both cofactors in worsening DR. Some but not all studies have shown a negative impact of high blood pressure on DR [9, 11, 12]. The UKPDS has demonstrated a significant correlation between systolic arterial hypertension and DR incidence in T2DM. Thus, patients with blood pressure (BP) > 140 mmHg have a 2.8 times higher risk of developing DR than those with BP <125 mmHg. In the study of Lurbe et al. [13], in a cumulative exposure model, HbA1c and elevated diastolic BP values ​​are predictive factors for the occurrence and progression of RD. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), diastolic BP emerged as a significant risk factor for DR progression in T1DM, but no correlations were found for systolic BP or T2DM [14, 15]. Therapeutic lowering BP was found to have a protective role on retinal lesions in several studies supporting the recommendations for tight blood pressure control to further prevent visual loss n T2DM [9, 14, 16].

2.1.3 Lipidic disorders and serum LDL

Unlike glycemic control, the role of serum lipids in DR pathogenesis is less clear. There is no parameter in the lipid profile that is strictly associated with the incidence or progression of DR. However, elevated total cholesterol, LDL-cholesterol, Apo B and Apo B/Apo A ratio are correlated with the appearance of hard exudates, these being lipoprotein extravasations in the retinal capillaries. Hadjadj et al. showed that serum triglyceride levels are correlated with the occurrence of nephropathy and retinopathy in patients with T1DM [17]. Several randomized trials confirmed that the treatment of dyslipidemia can prevent the development of DR [14, 15, 18, 19, 20, 21].

2.1.4 Genetic predisposition

Several studies have revealed that in young adults with T1DM, genetic predisposition for the development of DR is connected with the presence of HLA DR3/DR4 antigens. Furthermore, different alleles for codification of cytokines and chemokines, as well as vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)beta1 were characterized, explaining different predisposition for DR in diabetic patients. VEGF plays a key role in increased microvascular permeability and neovascularization in proliferative diabetic retinopathy. The VEGF gene is located on chromosome 6 (6p21.3) and is highly polymorphic in the promoter region, correlated with VEGF expression and activity. In a study by Buranczynska et al., the presence of the D allele at −2549 in the promoter region of the VEGF gene enhanced gene expression [22]. The DD genotype was associated with DR but not with nephropathy, suggesting a cell-specific target of the VEGF isoform. In a study of Jalal and Kalia, regarding the polymorphism of VEGF genes in India, allele A and AA genotype of rs2146323 were significantly correlated both with incidence and with severity of DR [23]. Awata et al. described C (−634) G polymorphism of VEGF gene to be related to macular edema as well as diabetic retinopathy [24]. Ray et al. identified VEGF −460 C genotype to increase VEGF basal promoter activity by 71%, leading to a 2.5 increased risk of proliferative DR [25]. TGF beta signaling is considered to have an immunosuppressive role in the retina. Disorders affecting this pathway lead, at least in experimental animal models, to loss of pericytes, microaneurysms and leakage, finding resembling diabetic retinopathy [26]. Beránek et al. found a more frequent incidence of 915G/C (R25P) polymorphism of TGF beta gene in patients with DR compared to control subjects [27].

2.1.5 Pregnancy

Hormonal alterations during pregnancy were found to be an independent risk factor both for onset and for progression of DR, especially PDR, posing many challenges regarding the management of these patients [28, 29, 30]. Another mechanism is pregnancy-induced hypertension and pre-eclampsia [31].

2.1.6 Ocular and systemic inflammation

Recent studies focus on the significance of inflammation in the developments of DR [32, 33, 34, 35, 36]. There is strong evidence that ischemia and retinal hypoxia induce release of VEGF and inflammatory molecules at the level of endothelial and glial cells. Furthermore, several studies support the idea that ocular inflammatory disorders, such as prolonged post cataract surgery healing, uveitis, keratitis, are related to DR progression [32, 33, 34, 35, 36].

There are increased evidences that chronic systemic inflammation is also related to increased risk of DR onset and progression. In an experimental animal model, recurrent exposure to systemic LPS leads to injury of capillary endothelium and in vivo thinning of the retina in hyperglycemic mice, but not in healthy controls [37]. There are clinical evidences of increased incidence of DR and PDR in long standing non-healing foot ulcer, that could be explained due to the associated chronic low-grade systemic inflammation [38, 39, 40, 41, 42].

2.1.7 Antidiabetic treatment and macular edema

The correlations between antidiabetic mellitus medication and the risk of macular edema is still a subject of research. In a comprehensive systematic review and meta-analyses, Zhu and col. found that insulin use, as well as thiazolinedione (TZD) and meglitinide might increase the risk of macular edema, metformin has no statistically significant effect, while the use of sulfonylureas seems to have a protective role [43]. The physiopathological mechanisms are not completely understood, but experimental studies indicate that insulin and TZD may induce changes in retinal flow and increased expression of VEGF and breakdown of retinal-vascular barrier [43, 44, 45, 46].

2.2 Pathophysiology

The pathological changes that lead to diabetic retinopathy are attributable to 3 main factors:

  • small vessel wall damage:

  • changes in blood flow

  • alterations in platelet function

2.2.1 Lesions in small vessel wall

Microvascular changes in the retinal capillaries are due to chronic hyperglycemia by different mechanisms, such as:

2.2.1.1 Aldose-reductase and intracellular polyol pathway

Aldose reductase is an enzyme that converts glucose to sorbitol, which induces osmotic stress by intracellular accumulation. In animal models, this phenomenon leads to microaneurysmal dilatations of the vascular wall, basal membrane thickening and loss of the pericytes [47]. However, experimental studies of treatment with aldose reductase inhibitors have not obtained satisfactory clinical results.

2.2.1.2 Advanced glycosylated end products (AGEs)

Chronic hyperglycemia leads to non-enzymatic glycation or glycoxidation of proteins, resulting in accumulation of AGEs. This process affects both intra- and extracellular proteins, resulting in functional impairment. Deposits of AGEs in the extracellular matrix and subendothelial space lead to permanent alterations of intercellular junctions, monocyte migration and activation of nuclear factor (NF)-κB along with activation of pro-inflammatory pathways [48, 49]. In experimental models, increased AGEs accumulation is associated with loss of pericytes and microaneurysm formation in retinal capillaries [50].

2.2.1.3 Oxidative stress and ROS

Hyperglycemia induces mitochondrial dysfunction and endoplasmic reticulum stress, with increased production of free radicals and reactive oxygen species (ROS) accumulation [49]. These degrade lipids, proteins and ribonucleic acid (RNA) chains. Furthermore, experimental studies have proved a “hyperglycemic memory”: in subjects with long periods of poor glycemic control, reversal of hyperglycemia fails to normalize increased oxidative activity in the retina [51]. Treatment with antioxidants and vitamin E alleviates endothelial dysfunction, but does not prevent the onset and progression of DR and other microvascular complications. Isolated experimental blockade of each of these pathways does not stop retinal microvascular damage, suggesting that the effects of hyperglycemia are manifested at the cellular and extracellular levels. Recently, experimental and clinical studies have demonstrated that inflammation biomarkers and pathways play a significant role in the aggravation of lesions and the evolution towards retinal neovascularization. A large array of cytokines and chemokines were found in increased concentrations in patients with DM, both in ocular samples and in serum: interleukin (Il)1beta, Il 2, 4, 6, 8, TNFalfa and (monocyte chemoattractant protein) MCP-1 [38, 42, 52, 53, 54]. Recent works have revealed that the TXNIP/NLRP3 Inflammasome activation pathways may contribute to pathologic neovascularization encountered in advanced stages of PDR [50, 54, 55].

2.2.1.4 Nitric oxide (NO) deficiency

Hyperglycemia induces decreased synthesis and increased consumption of NO by multiple pathways: activation of protein kinase C (PKC) in endothelial cells, oxidation of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) via aldose reductase pathway, and non-enzymatic production of superoxide by AGEs. NO plays key roles in microcirculation, by regulation of arteriolar tone, platelet stabilization and preventing leukocyte adherence at the vascular wall. Decreased local levels of NO promotes vasoconstriction, microvascular occlusions and secondary retinal ischemia.

2.2.2 Changes in blood flow and platelet function

General changes in blood favor small vessel obstructions with secondary retinal ischemia:

  • increased hematocrit and blood viscosity related to high liver synthesis of fibrinogen and alfa2 globulins

  • more rigid erythrocytes, with increased tendency to thrombosis

  • increased platelet adhesion and aggregation

  • activation of peripheral leukocytes, increased adherence to endothelial cells via beta-2 integrin expression and synthesis of mediators of inflammation

2.2.2.1 Pigmented Epitelium Derived Factor (PEDF) decrease and retinal neurodegeneration

PEDF is a trophic factor expressed by a multitude of retinal cells, an antagonist of VEGF. It decreases vascular permeability and plays an antioxidant role, protecting retinal cells from ROS. In the experimental setting, PEDF is decreased in aqueous and vitreous humor, early in preclinical stages of DR. The pathogenic mechanisms are supposed to be related with decreased insulin, as well as increased toxic mediators, such as glutamate. These early changes may induce mild changes in color vision, contrast sensitivity, visual field and electroretinogram oscillatory potentials [56, 57, 58, 59, 60].

All these molecular mechanisms may lead to:

  • alteration of tight junctions in endothelial cells, compromising the blood-retinal barrier, increasing extravasation of fluid in the retinal space and the formation of lipoprotein exudates and retinal edema

  • loss of pericytes, with the appearance of focal vascular dilations and microaneurysms

  • thickening, hyalinization of the basement membranes, with loss of elasticity of the vascular wall and autoregulatory capacity. This, together with the alterations of blood flow and platelets, favors microvascular occlusions, with the appearance of ischemic, hypoxic retinal areas.

The first areas affected by thrombosis and ischemia are in the middle retinal periphery, and the answer is to release a range of mediators, of which the key role is played by VEGF, which promotes retinal neovascularization and interruption of blood flow in many areas (optical disc, macula, iridocorneal angle and iris). The response to retinal hypoperfusion, a maladaptive protective mechanism, leads to the appearance of fragile new vessels, prone to repeated bleeding and leakage, ultimately destroying normal retinal architecture (Figure 1).

Figure 1.

Pathogenesis of diabetic retinopathy.

2.3 Clinical manifestations of DR

Fundus examination documents the presence and severity of retinal lesions. Clinical signs include:

  • Microaneurysms:tiny round red dots, typically located initially temporal to the fovea; sometimes hard to be differentiated from dot hemorrhages in ophthalmoscopy; they are best shown by fluorescein angiography

  • Retinal hemorrhages: a) “dot-blot” hemorrhages result from the venous end of the capillaries and are located in the middle layer of the retina; b) “flame-shaped” hemorrhages arise from pre-capillary arterioles and are located more superficially in the retinal nerve fiber layer

  • Retinal edema:elevated, white-greyish appearance of the involved area; may be a consequence of leakage and fluid accumulation or of retinal ischemia (intracellular retinal edema). When foveal region is involved, it may assume a cystoid appearance and fluorescein angiography reveal a flower-petal pattern

  • Hard exudates:these are well delineated, small, bright yellowish retinal lesions, formed by extravasated lipoproteins and lipid-filled macrophages and are mainly located in the outer plexiform layer. They are considered a sign of current or previous macular edema. When located in the macular region, they tend to organize in a circinate manner. They could resorb spontaneously months after the leakage is stopped, otherwise, chronic leakage leads to enlargement of the exudates and cholesterol accumulation.

  • “Cotton wool” spots: these are small, whitish, fluffy superficial lesions, that cover the underlying retinal vessels and bear the significance of focal retinal ischemia and infarction. They are composed by neuronal debris and can disappear in time by autolysis and phagocytosis.

  • Venous loops and venous beading (VB):these frequently occur adjacent to areas of nonperfusion and bear the significance of increasing retinal ischemia

  • Intraretinal microvascular abnormalities (IRMA):these are arteriolo-venous shunts, bypassing the capillary bed, and are considered an indicator of capillary occlusion and retinal ischemia. Together with VB, they are considered the most significant predictor of progression to PDR [58].

  • Neovessels:these are thin, with a single cell layer wall, extremely fragile, with a lace-like appearance and may be situated at the surface of the optic disk or elsewhere, in general at the periphery of the areas of non-perfusion. They can be best evidenced by fluorescein angiography and optical coherence tomography (OCT).

2.4 Staging of DR

Dr is classically referred as: non-proliferative (NPDR) and proliferative (PDR). The classification is determined by the presence of retinal neovascularization. Recent Guidelines of International Council of Ophthalmology for Diabetic Eye Care recommends the following staging system, based on findings encountered in ophthalmoscopy, to be used in clinical practice (Table 1).

DRFindings on Dilated Ophthalmoscopy
No apparent DRNo abnormalities
Mild NPDR*Microaneurysms only
Moderate NPDRMicroaneurysms + other signs:
  • dot and blot hemorrhages

  • hard exudates

cotton wool spots
Severe NPDRModerate NPDR with any of the following:
  • Intraretinal hemorrhages ≥20 in each quadrant;

  • Definite venous beading (VB) in 2 quadrants;

  • Intraretinal microvascular abnormalities (IRMA) in 1 quadrant;

and no signs of proliferative retinopathy
PDR*Severe non-proliferative DR + one of the followings:
  1. Neovascularization

Vitreous/preretinal hemorrhage

Table 1.

International Classification of Diabetic Retinopathy [57].

*NPDR: non proliferative diabetic retinopathy; *PDR: proliferative diabetic retinopathy

The ICO guidelines also refer to the location, extension of the diabetic macular edema (DME), as it is an important cause of decreased vision in DR, even in the absence of neovessels. Central involved DME is considered to be an area of retinal thickening in the macula that does involve the central subfield zone (of 1 mm in diameter).

2.5 Clinical forms of DR associated with high risk of vision loss

Diabetic maculopathy is the most frequent cause of decreased vision encountered in patients with T2DM. It can be manifest in every stage of the DR and represents the involvement of the fovea by hard exudates, macular edema due to fluid extravasation or by macular ischemia. In early stages, the loss of vision is mild; however, if untreated, it can may to permanent photoreceptor damage.

DME is considered clinically significant if [61, 62, 63]:

  • located at or within 500 μm of the center of the macula

  • hard exudates at or within 500 μm of the center if associated with thickening of adjacent retina

  • the area of retinal thickening is larger than one optic disc area and is located within 1 disc diameter of the center of macula

2.5.1 Advanced diabetic ocular disease

Advanced diabetic disease can remain asymptomatic for a long period of time, due to slow proliferation of the retinal neovessels and their location, usually in mid-periphery. It consists of retinal neovessels that grow into elevated fibrovascular membranes that enter the vitreous body, leading to serious complications: vitreous hemorrhage and retinal detachment [62]. Proliferation of the abnormal vessels at the level of iris and iridocorneal angle led to neovascular glaucoma, with poor clinical outcomes. Ophthalmological periodical screening is extremely important in early identifying and referral to laser therapy. In advanced stages, serious complications appear and the vision loss is irreversible.

Diabetic maculopathy is the most frequent cause of decreased vision encountered in patients with T2DM.

2.6 Diagnosis of DR

Early detection of DR depends on educating DM subjects, as well as their families, friends, and health care providers about the importance of regular eye examination. This holds true for asymptomatic subjects as well.

Initial ophthalmological examination in a patient with suspected/confirmed DR should include the following:

  • Visual acuity

  • Measurement of intraocular pressure (IOP), due to the possible risk of developing neovascular glaucoma

  • Slit-lamp exam +/- gonioscopy if iris neovascularization is observed or IOP is elevated

  • Fundus examination with dilated pupil

A variety of imaging techniques are useful to detect, classify and monitor DR, as well as efficacy of treatment: fundus photography, fluorescein angiography, optic coherence tomography (OCT) and OCT angiography.

2.6.1 Ophthalmoscopy and Fundus Photography

Currently, the two most sensitive methods are retinal photography and slit-lamp examination through dilated pupils. Direct ophthalmoscopy by ophthalmologists or trained technicians yields 80% sensitivity and >90% specificity [64]. It is cheap and is considered the method of choice. Fundus photography has the advantage of creating a permanent record, and for that reason, it is the preferred method for retinopathy assessment (Figures 24).

Figure 2.

“Background” diabetic retinopathy: few dot hemorrhages (blue arrows) (Dr. Ana Dascalu’s private collection, Emergency University Hospital Bucharest, Ophthalmology Department).

Figure 3.

Retinophotography: Severe NPRD: multiple dot and blot hemorrhages, hard exudates, cotton wool spots (blue arrows), macular edema, VB (green arrow) and IRMA (black arrows) (Dr. Daniela Stana’s private collection, Emergency University Hospital Bucharest, Ophthalmology Department, PhD thesis).

Figure 4.

Incipient PDR: large ischemic area situated temporally to the macular region, with hard exudates, dots hemorrhages, venous loops, IRMA and intraretinal neovessels; in the mid periphery, pigmented lesions post laser photocoagulation (Dr Ana Dascalu’s private collection, Emergency University Hospital Bucharest, Ophthalmology Department).

2.6.2 Fluorescein angiography

Fluorescein angiography is an invasive, costly, and time-consuming technique but is a sensitive method to detect vascular changes due to rupture of the inner and outer blood retinal barrier in the course of DR [63, 65, 66]. The retinal vasculature is visualized with great accuracy: the examiner may identify tiny microaneurysms and differentiate between microaneurysms (hyperfluorescent) and punctiform hemorrhage (hypofluorescence by masking effect). It is an indispensable exploration before planning different laser treatment, for example to distinguish retinal edema by leakage (which appears white due to dye accumulation) from ischemic retinal edema (which appears as hypofluorescent). In the latter case, the application of laser impacts is not recommended because it leads to exacerbation of retinal ischemia (Figure 5).

Figure 5.

Fluorescein Angiography: Severe NPRD: numerous microaneurysms (hyperfluorescent dots), areas of non-perfusion (hypofluorescent, blue arrows), venous loops and IRMA, with diffuse leakage (hyperfluorescent, red arrow) (Dr Daniela Stana’s private collection, PhD Thesis, Emergency University Hospital Bucharest, Ophthalmology Department).

2.6.3 Optical coherence tomography (OCT) and OCT-angiography (OCT-A)

OCT is a completely non-invasive, reproducible and quantifiable. It provides high-resolution images of the retinal layers, choroid, vitreous gel, and the vitreoretinal interface and has become the gold standard for diagnosis, assessment of treatment response, and follow-up up of patients with diabetic macular edema.

OCT angiography (OCTA) is a new non-invasive imaging technique that employs motion contrast imaging to high-resolution volumetric blood flow information, rapidly generating images similar to angiographic images [63, 65, 66, 67]. It provides a highly detailed view of the retinal vasculature, which allows for accurate delineation of the foveal avascular zone (FAZ) and detection of subtle microvascular abnormalities, including FAZ enlargement, areas of capillary non-perfusion, and intraretinal cystic spaces [66]. The possibility of detecting microvascular changes in diabetic eyes before the presence of visible microaneurysms may have important implications in the future. In this sense, OCTA could be able to quickly identify subjects at risk of DM (Figures 6 and 7).

Figure 6.

Optical coherence tomography (OCT) macular change analysis (before and 1 month after intravitreal anti = VEGF): hard exudates intraretinal edema with disorganization of the normal foveal architecture; macular and paramacular temporal edema decreases in area and height (Dr. Ana Dascalu’s private collection, Emergency University Hospital Bucharest, Ophthalmology Department).

Figure 7.

OCT-A: (a) enlargement of FAZ and perifoveolar area of microvascular abnormalities; (b) mild FAZ enlargement, multiple microaneurysms (Dr. Daniela Stana’s private collection, PhD Thesis, Emergency University Hospital Bucharest, Ophthalmological Department).

2.7 Treatment

2.7.1 Primary prevention

Follow-up of patients with DR involves the ophthalmologist and the diabetologist. Extensive studies in large groups of diabetic patients have shown the beneficial role of strict control of blood glucose, hypertension and dyslipidemia in both preventing and slowing the progression of DR. DCCT and UKPDS showed the importance of a good glycemic control in preventing microvascular damage in diabetes [68, 69]. Furthermore, every decrease with 10 mm Hg of systolic blood pressure is associated with a reduction of 35% in the risk of DR progression and of 50% in the risk of blindness [69]. Maintaining HbA1c below 7.0% (53 mmol/mol) and a systolic blood pressure below 140 mmHg is considered a realistic therapeutic target in clinical practice. Currently, the recommended serum lipid levels in DM are an optimal LDL cholesterol concentration of <100 mg/dl and desirable triglycerides levels of <150 mg/dl [69, 70, 71, 72].

2.7.2 Retinopathy screening

DR remains clinically silent, a long period of time until damages become irreversible. Ophthalmologic monitoring of DM subjects is essential. Frequency of screening depends on the severity of DR and the co-existence of risk factors. The follow-up schedule recommended by the ICO (International Council of Ophthalmology) Guidelines for Diabetic Eye Care is presented in Table 2 [61].

DR stagingFollow-up Schedule for ophthalmologistsTherapy
No apparent DR1-2 yearsObservation
Mild NPDR6-12 monthsObservation
Moderate NPDR3-6 monthObservation
Severe NPDR<3 months;Pan-retinal photocoagulation should be considered
Proliferative DR<1 month;Pan-retinal photocoagulation
Stable (Treated) PDR6-12 monthsObservation
Diabetic Macular Edema severityFollow-up Schedule for management by ophthalmologists
Noncentral-involved DME3-6 month;Focal laser photocoagulation should be considered
Central-involved DME1-3 month;Focal laser photocoagulation/ anti- VEGF therapy should be considered
Stable DME3-6 monthObservation

Table 2.

ICO Guidelines for Diabetic Eye Care: screening and follow-up schedule for diabetic retinopathy.

2.7.3 Laser photocoagulation

2.7.3.1 Classical laser

Laser therapy has been used in DR for over 60 years and remains the mainstay of treating the ischemic retina. Applied early in severe NPDR and PDR, laser therapy leads to the prevention/regression of neovascularization and to the remission of retinal edema. Clinical studies confirm the effectiveness of laser photocoagulation by reducing vision loss by approximately 50% in patients with PDR. It is based on application of 1000-2000 laser shots, lasting 100 milliseconds, 200-250 mW of power with a size of 200-500 micrometers at the level of the middle and extreme periphery of the retina, spaced at a distance by a spot diameter, in order to destroy the VEGF-secreting ischemic retina. Immediate complications are related to eye discomfort (tingling sensation/low-intensity pain) and mild ocular inflammation (caused by retinal burns). For this reason, it is recommended to space the laser photocoagulation in 3-4 sessions. In the long run, potential complications include hemeralopia, "fan shaped" visual field changes, or even concentric narrowing of the visual field through widening of scars and subretinal fibrosis. Other less frequent side effects are membrane injury, with secondary choroidal neovascularization, damage of ciliary nerves with permanently mydriasis and loss of accommodation, uveal effusion, angle closure glaucoma, serous retinal detachment, and vitreous hemorrhage [73, 74, 75].

2.7.3.2 Multispot laser

This technique allows the delivery of laser shots in a much shorter time and in a semi-automatic manner. These are much finer and at a lower intensity, threshold or subthreshold, causing lesser heat and consequently inflammation in the pigmented retinal epithelium. Clinical studies have shown that the effectiveness of the method is similar to classical laser, but fewer complications are encountered regarding retinal scarring and the impact on the visual field.

2.7.3.3 Laser photocoagulation in diabetic macular edema (DME)

In the case of exudative non-central DME, laser treatment may be considered as an alternative or in combination with intravitreal injections with anti-VEGF. In this case, the laser spots are finer, with a size of 50-100 μm, and lower energy. Laser treatment is inefficient in the case of ischemic macular edema, and so fluorangiography is necessary before therapeutic planning. In the early treatment diabetic retinopathy study (ETDRS) study, when comparing laser photocoagulation with no treatment, there was a decrease in DME from 24% to 12% after 3 years follow-up, while visual acuity improved in only 3% of patients [76].

2.7.4 Intravitreal anti-VEGF

Clinical and experimental studies have revealed increased VEGF concentration in ocular samples early in the evolution of DR, documenting its role both in increased vascular permeability and in vascular proliferation. Hence, anti-VEGF agents were used first in the treatment of DME and later in PDR management [77] (Table 3).

Description of the moleculeFDA approvalDose
Pegaptanib
(Macugen; Eyetech Inc, Cedar Knolls, NJ, USA)
RNA aptamer that binds to the heparin binding site of the VEGF-A165 isomerFor wet age related macular degeneration only0.3 mg /0.09ml
Bevacizumab
(Avastin; Genentech, San Francisco, CA, USA)
Full-length recombinant humanized anti-VEGF monoclonal antibodyNo; “off-label” use1.25 to 2.5 mg
(0.05-0.1ml)
Ranibizumab
(Lucentis; Genentech, San Francisco, CA, USA/Novartis Ophthalmics, Basel, Switzerland)
Recombinant fragment of the humanized anti-VEGF monoclonal antibody; increased binding affinity for all VEGF isoformsYes0.3 or 0.5 mg in 0.05 mL
Aflibercept(Eylea; Regeneron, Tarrytown, NY, USA)Recombinant fusion protein of the binding domains of human VEGF-R1 and VEGF-R2, fused with the Fc domain of human IgG1
bind VEGF with greater affinity compared to other anti VEGF and prevent activation of VEGF-R
Yes2mg/0.05mL

Table 3.

Anti VEGF agents used in DME treatment.

Clinical studies showed that Pegaptanib is the least effective in preventing neovascularization. Comparative studies between bevacizumab, ranibizumab and aflibercept found that they are all effective to decrease DME. However, aflibercept is most powerful in subjects with worse visual acuity [77, 78]. Still, the effect of intravitreal anti- VEGF is temporary and intravitreal therapy should be repeated according to clinical outcome.

2.7.5 Intravitreal steroids

In cases of DME resistant to anti-VEGF therapy after 3 monthly injections, intravitreal triamcinolone injection or fluocinolone are a therapeutic alternative to reduce DME and improve vision [79]. Their main untoward effects are cataract and transient increase of intraocular pressure.

2.7.6 Surgical management of DR

Vitreoretinal surgery is crucial in managing advanced DR, in order to mitigate visual loss. Its main indications include vitreous hemorrhage interfering with photocoagulation, tractional and combined tractional and rhegmatogenous retinal detachment, dense premacular hemorrhage and DME with with vitreo-macular traction [80]. The objectives of surgical removal of the vitreous (vitrectomy) include removal of vitreous opacity (usually blood) and/or fibrovascular proliferation, relieving retinal traction, achieving retinal reattachment, and allowing completion of scatter laser photocoagulation. A large case series showed that sight threatening complications are rare and in approximately 90% of cases, vision is improved or stabilized [81]. Vitrectomy may also be beneficial for maculopathy when traction from the vitreous gel contributes to fluid accumulation.

3. Diabetic foot ulcers (DFUs)

3.1 Risk factors

The main risk factors of DFUs include DM duration and high HbA1c [82, 83, 84, 85, 86, 87, 88]. The EURO-Diab group has identified hypertension, smoking and lipid disorders (hypertriglyceridemia, hypercholesterolemia) as additional risk factors [82, 83]. In Western countries, the male sex appears to be more commonly affected, with a risk ratio of 1.6. The co-existence of other microvascular complications (DR, nephropathy) increases the risk of DFUs.

Precipitating trauma is important. However, history of trauma is only identified in 48% of patients with DFUs. By contrast, foot injury without an apparent cause usually results from repeated minor injuries by inappropriate footwear [88, 89, 90]. Amin and Doupis have estimated that 45-60% of DFUs are mainly due to neuropathy, while 45% of DFUs are due to both diabetic neuropathy and peripheral arterial disease [87]. Like DR, diabetic neuropathy is also a very frequent DM complication and its prevalence increases with DM duration [90]. The other important driver of DFUs is ischemia from peripheral arterial disease (PAD). Visual impairment, foot deformities and past history of DFU also increase the risk of DFUs [85, 86].

3.2 Pathophysiology

The underlying mechanisms of DFUs include diabetic neuropathy, PAD and infection.

Diabetic neuropathy may affect the motor, sensory and autonomic nerves. Thickening of the basement membranes, endothelial hyperplasia in the vasa nervorum lead to thinning of the vascular lumen and secondary ischemia [90, 91]. On the other hand, metabolic disorders caused by chronic hyperglycemia, with the formation of AGEs, polyol pathways, increased oxidative stress levels and enzymatic activation of PKC also have direct toxic effects on nerve fibers.

Autonomic neuropathy causes arteriolo-venular shunts with secondary decreased blood flow in capillaries, but also anhidrosis, resulting in dry skin, thin, prone to cracking and ulceration. Sensory neuropathy leads to sensory (inability to feel warm/cold, pain, pressure), rendering the foot prone to undetected acute or chronic traumas [90, 91]. Motor neuropathy leads to imbalance between plantar flexors and extensors, with characteristic deformities, such as hammer toe, claw toe etc, and leading to high planter pressures in some small foot areas [92, 93, 94].

PAD leads to lower-extremity ischemia. In diabetes, it is usually located in the infra-popliteal arteries, less so at the iliofemoral level [89, 95]. Ischemia portends even more ominous outcomes [91, 96].

Pesently, micro and macrocirculatory disorders are considered not as separate entities, but more as a continuum in DM [97], neovascularization of vasa vasorum, with secondary hemorrhages and platelet aggregation facilitating the progression of atherosclerosis and intraluminal obstruction.

DFUs are frequently infected. The most common germs involved are staphylococci and streptococci, but deep infections are usually polymicrobial including gram positive, gram negative and even anaerobic germs [98, 99]. Chronic hyperglycemia and chronic hypoxia predispose to severe infections [99].

3.2.1 Clinical signs-staging systems

DFU represents any full-thickness ulcer below the ankle in DM. The initial signs and symptoms depend on the pathophysiological mechanism involved (neuropathy and/or PAD). Subjects with diabetic neuropathy are usually initially asymptomatic, but a minority of them may later develop neuropathic symptoms (numbness, paresthesia, lancinating or burning pain) with nocturnal exacerbation. In the event of PAD, intermittent claudication or even ischemic rest pain and gangrene may develop (Figure 8).

Figure 8.

Distal toe gangrene and extensive infection and inflammation at the level of the forefoot and mid foot (Dr. Dragos Serban’s private collection).

Usually, DFUs develop in an area exposed to increased pressure, with a non-healing tendency, often neglected in early stages due to diminished pain sensation. In the vent of infection, signs of local inflammation may be added (redness, swelling, pain, pus secretion etc).

Several staging systems were developed in order to characterize the pathogenic pathway and the severity and extension of ulcer. The International Working Group on the Diabetic Foot Risk Classification System (IWGDF) refers mainly at the severity of neuropathy and coexistence or not of the peripheral ischemia [100], while the Wagner classification describes the extension and depth [101] (Tables 4 and 5).

Grade 0Intact sensation
Grade 1Diminished sensation
Grade 2Diminished sensation+ foot deformities (hammertoes, claw toes) +/-peripheral arterial disease
Grade 3Previous/present ulcer or amputation

Table 4.

IWGDF risk classification [96].

Grade 0No ulcer in high-risk patients
Grade 1Superficial ulcer
Grade 2Ulceration involving tendons, ligaments, muscles, joints, not exposed to bone, without cellulitis or abscess
Grade 3Deeper ulcers, with frequent bone complications of osteomyelitis, abscesses or cellulitis.
Grade 4Forefoot gangrene.
Grade 5Gangrene extended to midfoot/hindfoot

Table 5.

Wagner Classification of DFU [101].

3.3 Diagnosis

3.3.1 Clinical examination

Patient history is necessary to provide information on DM duration, glycemic control, associated risk factors and any prior lesions/amputations.

Clinical examination should look for skin disorders, foot deformities, nail lesions, blisters etc. also be documented. It must also include an evaluation of neuropathic deficits, PAD and infection. Signs of limb threatening infection include bullae, ecchymoses, soft tissue crepitus and rapid spread of infection [102, 103].

Evaluation of sensory neuropathyis very important to establish whether the patient has lost the protective sensation, making him prone to accidental trauma. Hot/cold discrimination, pain perception, light touch and vibration perception, as well as protective sensation must be tested [95, 96, 97, 98, 99]. The latter is best assessed by the 10 g Semmes Weinstein monofilament or the measurement of the vibration perception threshold (VPT) with a neurothesiometer [93, 94, 95, 102, 103]. Tendon reflexes and muscular strength are also a part of the examination [95, 96, 97, 98, 99]. Finally, sudomotor dysfunction (reduced sweat production) is best examined by the Neuropad indicator test, which is based on a colour change from blue to pink [96, 97]. Indeed, this test has recently been identified as an independent risk factor of DFUs at 5 years [104].

3.3.1.1 Peripheral neuropathy screening

Evaluation of bilateral sensorial neuropathy in clinical practice requires neurological trained specialist and electrophysiological tests, which an increased burden on the national healthcare systems. In order to better select the patients who are more probably affected by neuropathy, a simpler tool was developed in 1994, namely Michigan Neuropathy Screening Instrument (MNSI) [105, 106]. It comprises a 2-step evaluation: first, a 15-item self-administered questionnaire that is scored by summing abnormal responses, followed by lower extremity examination (deformities, non-healing ulcers), assessment of ankle reflexes and of vibratory sensation. According to Herman and col., a score of more than 4 should raise the suspicion of peripheral sensorial neuropathy [106].

3.3.1.2 Peripheral arterial disease

Documenting the presence and the severity of ischemia is extremely important. Examination includes: a) palpation of peripheral pulses at the dorsalis pedis and the posterior tibial arteries; b) measurement of the ankle-brachial index (ABI) by a Doppler device [99, 100]. ABI evaluates the ratio of systolic arterial pressure at the brachial over the ankle level [107, 108]. Normal values range between 0.9-1.3, while values exceeding 1.3 point to calcified, uncompressible arteries, in which case the test cannot be used [99]. Similarly, one may measure the toe-brachial index (TBI), given that small digital arteries are rarely calcified: TBI<0.7 confirms the diagnosis of PAD [108]. More sophisticated evaluation (ultrasound, angiography) are used when necessary, especially to guide interventional treatment [95, 96, 97, 98, 99].

3.3.1.3 Assessment of the severity of the infection

If infection is suspected, it is best to use a tissue culture to identifying pathogens [109, 110]. X-rays, computed tomography and magnetic resonance imaging are used to evaluate bone infection or abscess formation, as well as to guide surgical treatment [86, 96, 97].

3.4 DFU management

3.4.1 Prophylaxis of DFU

Patients at risk of DFU should be managed by an interdisciplinary approach, including a diabetologist, a vascular surgeon, a podiatrist, a general surgeon, an orthopedic surgeon, a plastic surgeon and other specialists [82, 94, 102]. Stringent glycemic control is essential both in primary prevention of DFU and in ensuring wound healing. Management of high blood pressure and dyslipidemia is also important [86, 96, 97].

High-risk patients need education about the importance of wearing comfortable footwear, rigorous local hygiene, keeping feet dry and avoiding possible causes of local trauma (including barefoot walking) and frequent self-examinations [86, 96, 97]. Callus debridement, off-loading, and correct treatment of nail pathology are simple but extremely efficient measures for the prevention of foot ulcers [86, 96, 97]. LEADER trial suggests that treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo [109].

3.4.2 Therapeutic management of DFUs: main principles

Management of DFUs is aimed at correcting the pathogenic triad of neuropathy, PAD and infection. Off-loading with appropriate footwear and/or casts, debridement of callus and/or necrotic tissue, revascularization (by-pass grafting or intraluminal angioplasty) and infection control are the top priorities [86, 96, 97]. These may be aided by special dressings, skin substitutes, growth factors and other modalities [111, 112, 113, 114, 115, 116]. Special care must be taken to recognize and promptly deal with emergencies requiring surgery and other urgent interventions [117].

4. Conclusions

Diabetic retinopathy and diabetic foot ulcer are both disabling complications, with a significant impact on the patient's quality of life and healthcare systems [118]. Microvascular impairment and local inflammation play a significant role in the both pathological mechanisms. Prevention and early detection, along with optimal control of blood sugar, hyperlipemia and arterial hypertension are the most efficacious measures against these fearful complications.

Conflict of interest

Peter Kempler has received honoraria from and/or is an advisory member of the following companies: Ely Lilly, Novo Nordisk, Novartis, Miro, Boehringer-Ingelheim, Woerwag-Pharma, Pfizer, Sanofi, Di-Care Zrt., 77 Elektronika Kft., Teva, Astra-Zeneca.

Download for free

chapter PDF

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Ana Maria Dascalu, Dragos Serban, Nikolaos Papanas, Peter Kempler, Manfredi Rizzo, Daniela Stana, Gabriela Roman and Anca Pantea-Stoian (March 10th 2021). Microvascular Complications of Diabetes Mellitus: Focus on Diabetic Retinopathy (DR) and Diabetic Foot Ulcer (DFU) [Online First], IntechOpen, DOI: 10.5772/intechopen.96548. Available from:

chapter statistics

49total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us